Drug Patents owned by Phathom
1. List of Voquezna Dual Pak drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7977488 | PHATHOM | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
Aug, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 3, 2027 |
| Generating Antibiotic Incentives Now (GAIN) | May 3, 2032 |
Drugs and Companies using AMOXICILLIN; VONOPRAZAN FUMARATE ingredient
NCE-1 date: 2031-05-04
Market Authorisation Date: 03 May, 2022
Treatment: NA
Dosage: CAPSULE, TABLET;ORAL
VOQUEZNA DUAL PAK family patents
11
United States
11
Japan
5
Peru
4
Spain
4
China
4
European Union
3
Brazil
3
Canada
3
Argentina
3
New Zealand
3
Korea, Republic of
3
Taiwan
3
Georgia
2
Hong Kong
2
Dominican Republic
2
Malaysia
2
Denmark
2
RS
2
Poland
2
Ukraine
2
Morocco
2
EA
2
Croatia
2
Cyprus
2
Chile
2
Portugal
2
Australia
2
Costa Rica
2
South Africa
2
Slovenia
1
Uruguay
1
Austria
1
Germany
1
Russia
1
Singapore
1
Norway
1
ME
1
Israel
1
Jordan
1
Mexico
1
Ecuador
1
Colombia
1
Tunisia
2. List of Voquezna Triple Pak drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7977488 | PHATHOM | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
Aug, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186411 | PHATHOM | Pharmaceutical composition |
Aug, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 3, 2027 |
| Generating Antibiotic Incentives Now (GAIN) | May 3, 2032 |
Drugs and Companies using AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE ingredient
NCE-1 date: 2031-05-04
Market Authorisation Date: 03 May, 2022
Treatment: NA
Dosage: CAPSULE, TABLET, TABLET;ORAL
VOQUEZNA TRIPLE PAK family patents
11
United States
11
Japan
5
Peru
4
Spain
4
China
4
European Union
3
Brazil
3
Canada
3
Argentina
3
New Zealand
3
Korea, Republic of
3
Taiwan
3
Georgia
2
Hong Kong
2
Dominican Republic
2
Malaysia
2
Denmark
2
RS
2
Poland
2
Ukraine
2
Morocco
2
EA
2
Croatia
2
Cyprus
2
Chile
2
Portugal
2
Australia
2
Costa Rica
2
South Africa
2
Slovenia
1
Uruguay
1
Austria
1
Germany
1
Russia
1
Singapore
1
Norway
1
ME
1
Israel
1
Jordan
1
Mexico
1
Ecuador
1
Colombia
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic